On September 18, 2022 Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics reported that it will present "Leveraging mRNA Based Gene Editing to Optimize Advancement of Safe and Cost-Effective IPSC Products" as part of the focus track on Innovations in Gene Engineering and Editing at the 7th Annual CAR-TCR Summit in Boston on September 19, 2022 (Press release, Exacis Biotherapeutics, SEP 18, 2022, View Source [SID1234619627]). As the leader of Exacis, Dr. Fiore has direct experience in the use of mRNA to reprogram somatic cells to iPSCs and using a proprietary mRNA-based gene editing platform to engineer the cells into NK and T cells for treatment of cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The advances we are making in genetic engineering for cell-based therapies are remarkable," said Dr. Fiore. "Translating this research into developing off the shelf iPSC-derived cell therapies that are safe and effective will have a significant impact on the future of medical care."
Topics covered in Dr. Fiore’s presentation will include:
Engineering stealthing edits and performance enhancements to iPSCs with mRNA-based gene edited tools for enhanced persistence and potency
Avoiding viral and DNA vectoring approaches and using a fusogenic lipid delivery system to transfect cells
Expanding iPSCs during differentiation to yield large numbers of allogeneic NK cell therapies using an innovative and capital efficient manufacturing approach
The presentation will take place at 2:00 pm ET on Monday, September 19.
The 7th Annual CAR-TCR Summit will be held September 19-22, 2022, in Boston, MA. The comprehensive forum focuses on the goal of engineering a disease-free world. Meeting attendees will explore discovery through to commercialization to deliver safe, effective, and commercially viable CAR and TCR therapies.